source
- Sanofi halts Phase 3 trial of riliprubart in rare neurological disorderSanofi announced it is ending the Phase 3 study of its antibody drug riliprubart aimed at treating a rare neurological disease. The decision follows a recommendation from an independent data monit…
- GSK to buy Nuvalent for $10.6B, gaining two lung-cancer drugs under FDA reviewGSK announced it will acquire Nuvalent, a biotech focused on lung cancer, in a transaction valued at about $10.6 billion. The deal gives GSK control of Nuvalent’s two experimental lung-cancer ther…